EndoChoice

EndoChoice is a medtech company founded in 2008, based near Atlanta, Georgia. It specializes in innovative products and services for gastroenterology, focusing on conditions such as colon cancer. The company quickly established itself as a leader in the field, achieving significant growth and recognition, including a spot on the Inc. 500 list. By 2016, EndoChoice reported $75 million in profits and was acquired by Boston Scientific for $210 million. The company's product portfolio includes advanced endoscopic imaging systems, such as the Full Spectrum Endoscope (FUSE®), which offers a 330-degree field of vision. EndoChoice also provides single-use devices, infection control products, and pathology services tailored for GI specialists. With a commitment to optimizing supply chain logistics, EndoChoice ensures rapid delivery and high product standards to over 2,500 customers in the U.S. and 34 countries, enhancing the efficiency and sustainability of its operations.